Get the Stockscreener App
1.56
4.00%
0.06
Neumora Therapeutics Inc stock is traded at $1.56, with a volume of 483.87K.
It is up +4.00% in the last 24 hours and up +20.93% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.50
Open:
$1.5
24h Volume:
483.87K
Relative Volume:
0.34
Market Cap:
$252.63M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.6155
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-1.89%
1M Performance:
+20.93%
6M Performance:
-7.69%
1Y Performance:
-86.19%
1-Day Range:
$1.50
$1.60
1-Week Range:
$1.39
$1.6994
52-Week Range:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.56 | 242.92M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by XTX Topco Ltd - MarketBeat
Federated Hermes Inc. Invests $285,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
William Blair Has Positive Estimate for NMRA FY2029 Earnings - MarketBeat
Neumora's Q2 2025 Earnings Call: Unpacking Key Contradictions in M4 PAM Safety, Obesity Focus, and KOASTAL Studies - AInvest
Q3 EPS Estimate for Neumora Therapeutics Boosted by Analyst - MarketBeat
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c) - MSN
Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive
Neumora Therapeutics Faces Challenges as It Transitions to Full Public Company Compliance - TipRanks
Neumora Therapeutics’ Earnings Call Highlights Promising Pipeline - TipRanks
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215 - MSN
Stifel maintains Hold rating on Neumora Therapeutics stock at $2.00 By Investing.com - Investing.com Canada
Promising Developments and Pipeline Progress Drive Buy Rating for Neumora Therapeutics - TipRanks
Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215 - TipRanks
Earnings call transcript: Neumora Therapeutics beats Q2 2025 EPS estimates - Investing.com
Neumora Therapeutics Reports Q2 2025 Financial Results - TipRanks
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neumora Targets $180B Obesity Market with New Brain-Penetrant Drug, Reports 6 Clinical Readouts Coming - Stock Titan
Neumora Therapeutics to Report Q2 2025 Financial Results on August 6, 2025 - AInvest
Neumora Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
How volatile is Neumora Therapeutics Inc. stock compared to the marketUnprecedented market success - Jammu Links News
Why is Neumora Therapeutics Inc. stock attracting strong analyst attentionSignificant capital appreciation - Jammu Links News
Does Neumora Therapeutics Inc. stock perform well during market downturnsCapitalize on fast-growing stocks today - Jammu Links News
How does Neumora Therapeutics Inc. generate profit in a changing economyCapitalize on market trends with expert guidance - Jammu Links News
Is it the right time to buy Neumora Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
What institutional investors are buying Neumora Therapeutics Inc. stockAchieve triple-digit returns with smart investing - Jammu Links News
What are the latest earnings results for Neumora Therapeutics Inc.Capitalize on market momentum for maximum profit - Jammu Links News
What are analysts’ price targets for Neumora Therapeutics Inc. in the next 12 monthsAI Powered Tips With High Returns - Jammu Links News
Neumora Therapeutics (NMRA) Projected to Post Earnings on Wednesday - MarketBeat
How strong is Neumora Therapeutics Inc. company’s balance sheetExpert Picks Entry Points For 2025 - Jammu Links News
What is the dividend policy of Neumora Therapeutics Inc. stockPost Market Planner That Work - Jammu Links News
How many analysts rate Neumora Therapeutics Inc. as a “Buy”Chart Pattern Updates For Fast Growth - Jammu Links News
What are the technical indicators suggesting about Neumora Therapeutics Inc.Chart Pattern Guidance To Watch Now - Jammu Links News
Key metrics from Neumora Therapeutics Inc.’s quarterly dataTrade Insight With Community Collaboration Supported - metal.it
What are Neumora Therapeutics Inc. company’s key revenue driversAI Powered Planner Backed By Experts - Jammu Links News
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionStrong Buy With Technical Confidence Supported - beatles.ru
Published on: 2025-07-30 12:15:41 - metal.it
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - MSN
Mizuho Boosts Neumora Price Target to $5, Maintains Outperform Rating - AInvest
Pegasystems Delivers Strong Q2 Results, Raises Price Target to $58 - AInvest
Published on: 2025-07-29 01:24:00 - metal.it
What is Neumora Therapeutics Inc. company’s growth strategyNavigate market volatility with smart strategies - jammulinksnews.com
When is Neumora Therapeutics Inc. stock expected to show significant growthCapitalize on market trends with expert guidance - Jammu Links News
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):